FindTrial
Sign In

Cost-effectiveness of balancing stroke and bleeding risk using CHA2DS2-VASc in primary care patients with Atrial Fibrillation: a management study. CAFe

Cost-effectiveness of balancing stroke and bleeding risk using CHA2DS2-VASc in primary care patients with Atrial Fibrillation: a management study. CAFe - The CAFe study

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON37422
Enrollment
1250
Registered
2012-05-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation stroke

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with known (paroxysmal or chronic) AF that are primarily treated by their general practitioner.

Exclusion criteria

Exclusion criteria: Being unable to give informed consent Valvular disease or prosthetic valve

Design outcomes

Primary

MeasureTime frame
Ischemic stroke or severe bleeding—

Secondary

MeasureTime frame
Health status as determined by SF-36 and EQ-5D questionnaires at baseline, 12 months and 24 months follow-up—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)